CEO of Sequenom Inc. (SQNM, Financial) Harry F. Hixson Jr. bought 50,000 shares on 08/01/2012 at an average price of $2.92. The total transaction amount is $146,000. Sequenom Inc. is in the field of industrial genomics. Sequenom Inc. has a market cap of $367.7 million; its shares were traded at around $3.05 with and P/S ratio of 6.6. Sequenom Inc. had an annual average earnings growth of 14.5% over the past five years.
Aside from the company’s CEO, Sequenom CFO Paul Maier also purchased 10,000 shares of the company on 8/1/2012 at the average price of $2.86. Various other insiders, including Executive Vice President Ronald Lindsay and Director John Fazio, also have increased their positions in the company in recent months.
Mr. Harry F. Hixson Jr., Ph.D., has been CEO of Sequenom Inc. since Sept. 28, 2009 and previously served as its Interim CEO. Dr. Hixson co-founded BrainCells Inc. and served as its CEO from July 2004 to September 2005. He served as the CEO of Elitra Pharmaceuticals Inc. from February 1998 to May 2003 and served as its president from June 1998 to May 2003.
SQNM has an average annual revenue growth of -17.7% for the past 10 years, and an average revenue growth of -11.1% during the last 12 months. Earnings per share have been all negative during the past 10 years, although figures have improved throughout the years. The company holds $84.28 million in cash, and owes $13.27 million in long-term debt. Sequeonom has a predictability rating of 1 star.
No gurus currently hold any position in SQNM.
Aside from the company’s CEO, Sequenom CFO Paul Maier also purchased 10,000 shares of the company on 8/1/2012 at the average price of $2.86. Various other insiders, including Executive Vice President Ronald Lindsay and Director John Fazio, also have increased their positions in the company in recent months.
Mr. Harry F. Hixson Jr., Ph.D., has been CEO of Sequenom Inc. since Sept. 28, 2009 and previously served as its Interim CEO. Dr. Hixson co-founded BrainCells Inc. and served as its CEO from July 2004 to September 2005. He served as the CEO of Elitra Pharmaceuticals Inc. from February 1998 to May 2003 and served as its president from June 1998 to May 2003.
SQNM has an average annual revenue growth of -17.7% for the past 10 years, and an average revenue growth of -11.1% during the last 12 months. Earnings per share have been all negative during the past 10 years, although figures have improved throughout the years. The company holds $84.28 million in cash, and owes $13.27 million in long-term debt. Sequeonom has a predictability rating of 1 star.
No gurus currently hold any position in SQNM.
